Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 63

Results For "City"

1529 News Found

Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
News | August 13, 2024

Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr

Morepen Labs successfully raised Rs. 200 Crore through QIP


Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years
Policy | August 10, 2024

Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years

The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024


32 projects completed under PLI Scheme for promotion of domestic manufacturing of Critical KSMs/DIs and APIs
Policy | August 10, 2024

32 projects completed under PLI Scheme for promotion of domestic manufacturing of Critical KSMs/DIs and APIs

Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme


Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut
Healthcare | August 07, 2024

Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut

Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care


Lupin completes  successful Phase 3 trials for Lucentis biosimilar
Biotech | August 06, 2024

Lupin completes successful Phase 3 trials for Lucentis biosimilar

The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU


SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
News | August 06, 2024

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024


Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr
News | August 02, 2024

Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr

Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore


GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s  CHMP opinion for adults aged 50-59
Drug Approval | July 30, 2024

GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s CHMP opinion for adults aged 50-59

Decision on EU marketing authorisation for this population expected by September 2024


Steps taken by India for preparedness against future pandemics
Policy | July 29, 2024

Steps taken by India for preparedness against future pandemics

Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting